Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Estonian Subsidiary Seeks EU Clearance for Lung Cancer Dx

NEW YORK, Sept. 27 (GenomeWeb News) - CeMines said today that its Estonian subsidiary has filed for CE Mark registration for its gene expression-based lung cancer diagnostic.


CeMines filed for clearance through a Swedish business partner, Trial Form Support AB.


Golden, Colo.-based CeMines seeks EU clearance for clinical use of CellCorrect Lab test kits, which use a combination of its CellCorrect gene-expression-based auto-antibody detection technology, Molecular FingerPrinting statistical analysis platform, and a proprietary library of lung cancer biomarkers.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.